Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Financial Collapse of 2001 Unwinding -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Voodoo who wrote (4826)	3/16/2020 3:50:58 AM
From: elmatador	Respond to of 13803

My Facebook feed named Quarantine last Saturday

To: Dr. Voodoo who wrote (4826)	3/16/2020 4:42:10 AM
From: elmatador	2 Recommendations Recommended By DinoNavarre Dr. Voodoo Respond to of 13803

As soon as we get QE, TARP 2.0 and that sucking sound of money flooding the market, it will be time for Covid-19 to slowly take tyhe back seat and disappear...

To: Dr. Voodoo who wrote (4826)	3/17/2020 7:56:31 AM
From: elmatador	1 Recommendation Recommended By Dr. Voodoo Respond to of 13803

First Person Injected With (Moderna) Trial Coronavirus Vaccine In Seattle Mar 17, 2020,12:16am EST A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical ... [+] ASSOCIATED PRESSA new phase 1 clinical trial of a potential vaccine for the SARS-CoV2 coronavirus began on Monday in Seattle, with the first person to enroll in the trial receiving the vaccine. The vaccine, mRNA-1273, was developed by biotechnology company Moderna in combination with researchers from the National Institutes of Health (NIH). The trial is being conducted at Kaiser Permanente Washington Health Research Institute in Seattle. The phase 1 study aims to test three different doses of the mRNA-1273 vaccine ad hopes to recruit 45 healthy adults for the initial trial. Participants will receive two shots of the vaccine, 28 days apart and will be monitored to evaluate both the safety and immunogenicity of the vaccine. The latter involves seeing how well the vaccine stimulates an immune response to a protein on the SARS-CoV2 coronavirus surface. The first person to get the vaccine was 43-year old Jennifer Haller from Seattle who said; “I hope that we get to a working vaccine quickly and that we can save lives and people can go back to life as soon as possible,” in an interview with TIME. “This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna in a press release. He added that Moderna is already working with the FDA and other organizations to prepare for a phase 2 trial, which would involve larger numbers of patients. The start of the trial comes just 65 days after Chinese authorities sequenced the SARS-CoV2 coronavirus. Just 2 days after that, researchers at the Vaccine Research Center at the NIH finalized the design of the vaccine and began to manufacture it, finishing the first batch on February 7th. On February 24th after analytical testing, the company shipped it to the NIH. “Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony S. Fauci, M.D., head of the National Institute of Allergy and Infectious Diseases, at the NIH. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal,” he added. The vaccine cannot cause COVID-19 and does not contain the virus as is the case with some other vaccines. Instead it contains a small piece of genetic code called mRNA which scientists have extracted from the virus and then expanded in the laboratory. In this case, the mRNA encodes the viral “spike” protein which is vital for the coronavirus to gain access to human cells. The researchers hope that the vaccine will stimulate the immune system to attack the virus, preventing the development of COVID-19. Kizzmekia Corbett, Ph.D., of NIAID's Vaccine Research Center discusses efforts to develop a vaccine against SARS-CoV-2, that causes COVID-19 in an interview conducted Jan. 28, 2020. Credit NIH/NIAID The mRNA-1723 vaccine was not tested in mice before beginning human clinical trials, an incredibly rare occurrence which has proved controversial. Some experts are insisting that the severity and urgent need of the current situation means this is justified, whereas others are concerned that this could break various ethical and safety standards and put trial participants at greater risk than normal. Although the design and production of the prospective vaccine was incredibly fast, evaluation of it will take considerable time. All of the participants will be followed for 12 months after the second vaccination to collect the data researchers initially need to figure out whether it is safe and effective. The study is still enrolling healthy people aged 18-55 in the Seattle area to help test the new vaccine

To: Dr. Voodoo who wrote (4826)	3/18/2020 1:13:27 PM
From: elmatador	3 Recommendations Recommended By chemist61 Dr. Voodoo Joseph Silent Respond to of 13803

99% of Those Who Died From Virus Had Other Illness, Italy Says The average age of those who’ve died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy’s victims under 40 have been males with serious existing medical conditions. While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms. According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country’s death rate closer to the global average of about 2%. By Tommaso Ebhardt Chiara Remondini and Marco Bertacche Open the link to see the graphics. bloomberg.com 18 de março de 2020, 12:56 WET We’re tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know. More than 99% of Italy’s coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country’s national health authority. After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease. Prime Minister Giuseppe Conte’s government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness. Italy Coronavirus DeathsBy prior illnesses (%) The new study could provide insight into why Italy’s death rate, at about 8% of total infected people, is higher than in other countries. The Rome-based institute has examined medical records of about 18% of the country’s coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions. More than 75% had high blood pressure, about 35% had diabetes and a third suffered from heart disease. Threat to the ElderlyThe median age of the infected is 63 but most of those who die are older The average age of those who’ve died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy’s victims under 40 have been males with serious existing medical conditions. While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms. According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country’s death rate closer to the global average of about 2%. — With assistance by Karl Maier, and Alessandro Speciale

To: Dr. Voodoo who wrote (4826)	3/19/2020 4:11:53 AM
From: elmatador	1 Recommendation Recommended By DinoNavarre Read Replies (1) \| Respond to of 13803

Italy too close to China: Many Italians in Northern Italy have sold their leather goods and textiles companies to China. Italy then allowed 100,000 Chinese workers from Wuhan and Wenzhou to move to Italy to work in these factories, with direct flights between Wuhan and Northern Italy. This continued post outbreak, so is it mere coincidence that Northern Italy is now Europe’s hotspot for Corona Virus? The murky reality is that the EU turned a blind eye to vast numbers of illegal Chinese immigrants working in Italian factories. The ‘Open Borders’ EU will of course try to keep this under wraps, but reality is, the Chinese Mafia operate Italian textile factories with tens of thousands of illegal immigrants shipping ‘made in Italy’ goods into China and elsewhere. Why didn’t the EU act to stop corrupt Italians taking backhanders from the Chinese mafia? Why is Boris and our Scientific community still happy to allow Italian flights into the UK? This is an area that logically should be front and centre of investigations into how the virus spread into Europe, but we suspect it will overlooked. The whole scenario is a disaster for the EU and their open borders narrative, but as the 4th biggest economy in the EU this whole situation with Italy could accelerate the collapse of the whole EU project. altnewsmedia.net